HQL 975

Drug Profile

HQL 975

Latest Information Update: 19 May 2003

Price : $50

At a glance

  • Originator Sumitomo Metal Industries
  • Class Antihyperglycaemics; Oxazoles; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 19 May 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Japan (PO)
  • 21 May 2001 Profile reviewed but no significant changes made
  • 30 Oct 1998 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top